BACKGROUND: There is increasing evidence that various types of drug-eluting stents (DES) may differ regarding the long-term safety and efficacy, particularly in complex lesion subsets. AIMS: In a cohort of consecutive patients undergoing bifurcation stenting, we sought to compare the 1-year efficacy and safety of the first-generation paclitaxel-eluting stents (PES), the first-generation sirolimus-eluting (SES) and the second-generation everolimus- or zotarolimus-eluting stents (EES/ZES). METHODS: We treated 2197 patients (mean age 67.5 years, 75.4 % male) with provisional T-stenting for de novo coronary bifurcation lesions using PES, SES or EES/ZES. Primary endpoint (MACE) was the composite of death from any cause, myocardial infarction (MI) and target lesion revascularisation (TLR). RESULTS: Side branch stenting was found to be clinically indicated in 793 patients (36.1 %). The cumulative 1-year incidence of MACE was 18.8 % after PES, 13.1 % after PCI with SES and 12.2 % after EES/ZES (p = 0.003), the combined endpoint death and MI occurred in 6.6, 5.6 and 8.3 % (p = 0.253) and death in 4.3, 5.2 and 5.3 % (p = 0.581), respectively. After adjustment for co-variables the type of DES was a significant (p = 0.008) predictor of MACE [HR (95 % confidence interval) PES vs SES 1.34 (1.04-1.71), PES vs. EES/ZES 1.75 (1.19-2.57), EES/ZES vs. SES 0.762 (0.531-1.095)], but not of death (p = 0.581), death and MI (p = 0.077) or stent thrombosis (ST) (p = 0.925). CONCLUSIONS: In de novo coronary bifurcation lesions treated with provisional T-stenting, SES and EES/ZES achieved better outcomes than PES by reducing the need for reintervention.
BACKGROUND: There is increasing evidence that various types of drug-eluting stents (DES) may differ regarding the long-term safety and efficacy, particularly in complex lesion subsets. AIMS: In a cohort of consecutive patients undergoing bifurcation stenting, we sought to compare the 1-year efficacy and safety of the first-generation paclitaxel-eluting stents (PES), the first-generation sirolimus-eluting (SES) and the second-generation everolimus- or zotarolimus-eluting stents (EES/ZES). METHODS: We treated 2197 patients (mean age 67.5 years, 75.4 % male) with provisional T-stenting for de novo coronary bifurcation lesions using PES, SES or EES/ZES. Primary endpoint (MACE) was the composite of death from any cause, myocardial infarction (MI) and target lesion revascularisation (TLR). RESULTS: Side branch stenting was found to be clinically indicated in 793 patients (36.1 %). The cumulative 1-year incidence of MACE was 18.8 % after PES, 13.1 % after PCI with SES and 12.2 % after EES/ZES (p = 0.003), the combined endpoint death and MI occurred in 6.6, 5.6 and 8.3 % (p = 0.253) and death in 4.3, 5.2 and 5.3 % (p = 0.581), respectively. After adjustment for co-variables the type of DES was a significant (p = 0.008) predictor of MACE [HR (95 % confidence interval) PES vs SES 1.34 (1.04-1.71), PES vs. EES/ZES 1.75 (1.19-2.57), EES/ZES vs. SES 0.762 (0.531-1.095)], but not of death (p = 0.581), death and MI (p = 0.077) or stent thrombosis (ST) (p = 0.925). CONCLUSIONS: In de novo coronary bifurcation lesions treated with provisional T-stenting, SES and EES/ZES achieved better outcomes than PES by reducing the need for reintervention.
Entities:
Keywords:
Bifurcation lesions; Drug eluting stents; PCI; Restenosis; Stent thrombosis
Authors: Antoinette de Waha; Salvatore Cassese; Duk-Woo Park; Francesco Burzotta; Robert A Byrne; Tomohisa Tada; Lamin A King; Seung-Jung Park; Albert Schömig; Adnan Kastrati Journal: Clin Res Cardiol Date: 2012-03-16 Impact factor: 5.460
Authors: George D Dangas; Patrick W Serruys; Dean J Kereiakes; James Hermiller; Ali Rizvi; William Newman; Krishnankutty Sudhir; Robert S Smith; Sherry Cao; Kleanthis Theodoropoulos; Donald E Cutlip; Alexandra J Lansky; Gregg W Stone Journal: JACC Cardiovasc Interv Date: 2013-09 Impact factor: 11.195
Authors: Xavier Freixa; Mahendra Carpen; Mark A Kotowycz; Kay-Woon Ho; Ahmed Krimly; Mark D Osten; Christopher B Overgaard; Eric M Horlick; Peter H Seidelin; Vladimír Džavík Journal: Can J Cardiol Date: 2012-04-21 Impact factor: 5.223
Authors: Masanori Taniwaki; Giulio G Stefanini; Sigmund Silber; Gert Richardt; Pascal Vranckx; Patrick W Serruys; Pawel E Buszman; Henning Kelbaek; Stephan Windecker Journal: J Am Coll Cardiol Date: 2014-02-13 Impact factor: 24.094
Authors: Aurel Toma; Barbara E Stähli; Michael Gick; Cathérine Gebhard; Thomas Nührenberg; Kambis Mashayekhi; Miroslaw Ferenc; Franz-Josef Neumann; Heinz Joachim Buettner Journal: Clin Res Cardiol Date: 2017-02-24 Impact factor: 5.460